Edwards Lifesciences Corporation $EW Shares Sold by Public Employees Retirement System of Ohio

Public Employees Retirement System of Ohio lessened its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 3.1% in the second quarter, according to its most recent filing with the SEC. The firm owned 240,089 shares of the medical research company’s stock after selling 7,609 shares during the quarter. Public Employees Retirement System of Ohio’s holdings in Edwards Lifesciences were worth $18,777,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of the business. Jennison Associates LLC raised its holdings in Edwards Lifesciences by 34.3% during the first quarter. Jennison Associates LLC now owns 10,086,033 shares of the medical research company’s stock worth $731,036,000 after purchasing an additional 2,576,383 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Edwards Lifesciences by 4.1% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 6,783,568 shares of the medical research company’s stock worth $491,673,000 after acquiring an additional 264,311 shares in the last quarter. Nuveen LLC acquired a new stake in Edwards Lifesciences during the 1st quarter valued at $330,881,000. Invesco Ltd. boosted its holdings in shares of Edwards Lifesciences by 2.6% during the first quarter. Invesco Ltd. now owns 4,287,712 shares of the medical research company’s stock worth $310,773,000 after purchasing an additional 107,241 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its stake in shares of Edwards Lifesciences by 5.3% in the first quarter. Charles Schwab Investment Management Inc. now owns 3,961,643 shares of the medical research company’s stock worth $287,140,000 after acquiring an additional 198,882 shares during the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, insider Larry L. Wood sold 8,950 shares of the stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $78.06, for a total value of $698,637.00. Following the sale, the insider directly owned 206,900 shares in the company, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, VP Daniel J. Lippis sold 4,114 shares of the business’s stock in a transaction on Monday, July 28th. The shares were sold at an average price of $79.46, for a total transaction of $326,898.44. Following the completion of the transaction, the vice president directly owned 22,002 shares of the company’s stock, valued at $1,748,278.92. This trade represents a 15.75% decrease in their position. The disclosure for this sale can be found here. 1.29% of the stock is currently owned by insiders.

Analyst Ratings Changes

EW has been the topic of several analyst reports. Truist Financial increased their price target on shares of Edwards Lifesciences from $81.00 to $82.00 and gave the stock a “hold” rating in a research note on Friday, July 25th. Mizuho boosted their price objective on shares of Edwards Lifesciences from $87.00 to $95.00 and gave the stock an “outperform” rating in a report on Friday, July 25th. Canaccord Genuity Group increased their target price on shares of Edwards Lifesciences from $75.00 to $81.00 and gave the company a “hold” rating in a research note on Friday, July 25th. BTIG Research raised Edwards Lifesciences from a “neutral” rating to a “buy” rating and set a $100.00 price target for the company in a report on Tuesday, July 29th. Finally, Barclays increased their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock an “overweight” rating in a research report on Friday, July 25th. Three analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, eight have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $86.61.

Edwards Lifesciences Price Performance

EW opened at $75.35 on Friday. The stock has a market capitalization of $44.24 billion, a P/E ratio of 10.84, a price-to-earnings-growth ratio of 3.59 and a beta of 1.07. The company has a debt-to-equity ratio of 0.06, a current ratio of 4.68 and a quick ratio of 3.87. The company’s 50 day simple moving average is $78.50 and its 200-day simple moving average is $75.62. Edwards Lifesciences Corporation has a one year low of $64.00 and a one year high of $83.00.

Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, July 24th. The medical research company reported $0.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.62 by $0.05. The business had revenue of $1.53 billion for the quarter, compared to analyst estimates of $1.49 billion. Edwards Lifesciences had a return on equity of 15.01% and a net margin of 72.96%.The firm’s revenue for the quarter was up 11.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.70 earnings per share. Edwards Lifesciences has set its Q3 2025 guidance at 0.540-0.60 EPS. FY 2025 guidance at 2.400-2.500 EPS. Sell-side analysts anticipate that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current fiscal year.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.